These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35737052)

  • 21. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.
    Finkel KW; Cohen EP; Shirali A; Abudayyeh A;
    Clin J Am Soc Nephrol; 2016 Dec; 11(12):2273-2279. PubMed ID: 27526708
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
    Sinisalo M; Silvennoinen R; Wirta O
    Am J Hematol; 2012 Jun; 87(6):640. PubMed ID: 22473521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Free light chains reduction on acute kidney injury in multiple myeloma: critical role of high cut-off membranes].
    Buti E; Dervishi E; Ghiandai G; Mjeshtri A; Paudice N; Terreni A; Caldini A; Nozzoli C; Minetti EE; Bergesio F
    G Ital Nefrol; 2014; 31(6):. PubMed ID: 25504169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Efficacy of SUPRA HFR in the treatment of acute renal damage during multiple myeloma].
    Daidola G; Guarena C; Brustia M; Leonardi G; Vigotti FN; Marciello A; Bianco S; Chiarinotti D; Saltarelli M; Besso L; Biancone L
    G Ital Nefrol; 2018 Dec; 35(6):. PubMed ID: 30550040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy.
    Kleeberg L; Morgera S; Jakob C; Hocher B; Schneider M; Peters H; Rötzer S; Müller C; Kaiser M; Fleissner C; Heider U; Neumayer HH; Sezer O
    Eur J Med Res; 2009; 14(2):47-54. PubMed ID: 19258212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymethylmethacrylate membrane and serum free light chain removal: enhancing adsorption properties.
    Fabbrini P; Sirtori S; Casiraghi E; Pieruzzi F; Genovesi S; Corti D; Brivio R; Gregorini G; Como G; Carati ML; Viganò MR; Stella A
    Blood Purif; 2013; 35 Suppl 2():52-8. PubMed ID: 23676837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
    Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
    Cockwell P; Cook M
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Removal of free light chains in hemodialysis patients without multiple myeloma: a crossover comparison of three different dialyzers.
    Donati G; Moretti MI; Baraldi O; Spazzoli A; Capelli I; Comai G; Marchetti A; Sarma M; Mancini R; La Manna G
    BMC Nephrol; 2016 Nov; 17(1):193. PubMed ID: 27884120
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.
    Bridoux F; Arnulf B; Karlin L; Blin N; Rabot N; Macro M; Audard V; Belhadj K; Pegourie B; Gobert P; Cornec Le Gall E; Joly B; Karras A; Jaccard A; Augeul-Meunier K; Manier S; Royer B; Caillot D; Tiab M; Delbes S; Suarez F; Vigneau C; Caillard S; Arakelyan-Laboure N; Roos-Weil D; Chevret S; Fermand JP;
    J Clin Oncol; 2020 Aug; 38(23):2647-2657. PubMed ID: 32574117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Light-chain removal by plasmapheresis in myeloma-associated renal failure.
    Cserti C; Haspel R; Stowell C; Dzik W
    Transfusion; 2007 Mar; 47(3):511-4. PubMed ID: 17319833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients.
    Pendón-Ruiz de Mier MV; Ojeda R; Álvarez-Lara MA; Navas A; Alonso C; Caballero-Villarraso J; Aljama P; Álvarez MA; Soriano S; Rodríguez M; Martín-Malo A
    BMC Nephrol; 2020 Jun; 21(1):227. PubMed ID: 32539688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The double polymethylmethacrylate filter (DELETE system) in the removal of light chains in chronic dialysis patients with multiple myeloma.
    Santoro A; Grazia M; Mancini E
    Blood Purif; 2013; 35 Suppl 2():5-13. PubMed ID: 23676829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myeloma kidney: advances in molecular mechanisms of acute kidney injury open novel therapeutic opportunities.
    Davenport A; Merlini G
    Nephrol Dial Transplant; 2012 Oct; 27(10):3713-8. PubMed ID: 23114897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of medium cutoff dialyzers in patients with multiple myeloma and acute kidney injury requiring hemodialysis: A systematic review.
    Koniman R; Teo SH; Kaushik M; Nagarajan C; Tan MSY; Tan HK; Ramirez MEG; Lim CC;
    Semin Dial; 2023 Jan; 36(1):12-17. PubMed ID: 35840146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of acute kidney injury with cast nephropathy.
    Walther C; Podoll AS; Finkel KW
    Clin Nephrol; 2014 Jul; 82(1):1-6. PubMed ID: 24725380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Favorable kidney recovery by extracorporeal light chain removal and anti-myeloma treatments in patients with newly diagnosed multiple myeloma and acute renal failure.
    Silvestrini G; Tatangelo P; Scaramucci L; Sfara G; Bondanini F; Niscola P; de Fabritiis P; Palumbo R
    Saudi J Kidney Dis Transpl; 2020; 31(6):1445-1447. PubMed ID: 33565464
    [No Abstract]   [Full Text] [Related]  

  • 38. [Management of Cast Nephropathy].
    De Simone E; Fenoglio R; Cortazzi S; Careddu A; Geraci G; Bugliosi F; Sciascia S; Roccatello D
    G Ital Nefrol; 2023 Oct; 40(Suppl 81):. PubMed ID: 38007838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Improved prognosis in light chain nephropathy due to multiple myeloma].
    Juul JS; Larsen T; Marcussen N; Pedersen EB
    Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Test of Serum Free Light Chain and Its Clinical Significance in Light Chain Multiple Myeloma].
    Song P; An ZM; Zhou XG; Li F; Wang LP; Zhao Q; Yu YP; Zhai YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1357-61. PubMed ID: 26524037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.